Expect a capital raise announcement within weeks as cash burn continues. The effectiveness of four separate shelves signals preparation for multiple or large offerings. Traders should watch for a prospectus supplement or 424B filing detailing the specific terms, any overnight offering at a discount would be a near-term negative catalyst.
Price Chart
How similar events traded
Executive Summary
Forte Biosciences had four shelf registration statements (File Nos. 333-296425, 333-283814, 333-274257, 333-224880) declared effective by the SEC on September 1, 2026. These EFFECT notices clear the way for the company to conduct offerings under each shelf, including the $500M universal shelf filed in June 2026. For a clinical-stage biopharma burning ~$22M/quarter with $58.2M cash, this makes near-term capital raising highly probable, creating a significant dilution overhang that outweighs any positive pipeline developments.
Key Facts
- Four shelf registration statements (File Nos. 333-296425, 333-283814, 333-274257, 333-224880) declared effective on September 1, 2026.
- The $500M universal shelf (File No. 333-296425) was previously filed on June 6, 2026 and is now effective.
- Forte is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026.
- The shelf represents massive potential dilution relative to the company's market cap, enabling the company to sell common stock, preferred stock, debt, and warrants.
Financial Impact
Up to $500M in securities can now be offered, representing substantial dilution relative to the company's market cap
Risk Factors
- Imminent dilutive offering likely given cash burn trajectory
- Potential for multiple offerings from separate shelf registrations
- No revenue to offset dilution, all funding must come from equity or debt markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (FBRX), Batch item 1 | 9999999995-26-002850 |
| Document: 9999999995-26-002850-index.html | 9999999995-26-002847 |
| Document: 9999999995-26-002850.txt | 9999999995-26-002846 |
| EFFECT Filing (FBRX), Batch item 4 | 9999999995-26-002847 |
| Document: 9999999995-26-002847-index.html | 9999999995-26-002850 |
| Document: 9999999995-26-002847.txt | 9999999995-26-002850 |
| EFFECT Filing (FBRX), Batch item 7 | 9999999995-26-002846 |
| Document: 9999999995-26-002846-index.html | 9999999995-26-002850 |
| Document: 9999999995-26-002846.txt | 9999999995-26-002850 |
| EFFECT Filing (FBRX), Batch item 10 | 9999999995-26-002843 |
| Document: 9999999995-26-002843-index.html | 9999999995-26-002850 |
| Document: 9999999995-26-002843.txt | 9999999995-26-002850 |
Track record
15 reports on FBRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Viewing Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers